These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

814 related articles for article (PubMed ID: 20385996)

  • 1. Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90.
    Tallen G; Ratei R; Mann G; Kaspers G; Niggli F; Karachunsky A; Ebell W; Escherich G; Schrappe M; Klingebiel T; Fengler R; Henze G; von Stackelberg A
    J Clin Oncol; 2010 May; 28(14):2339-47. PubMed ID: 20385996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Münster Group 87.
    Einsiedel HG; von Stackelberg A; Hartmann R; Fengler R; Schrappe M; Janka-Schaub G; Mann G; Hählen K; Göbel U; Klingebiel T; Ludwig WD; Henze G
    J Clin Oncol; 2005 Nov; 23(31):7942-50. PubMed ID: 16258094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia - long-term results of trial ALL-REZ BFM P95/96.
    Eckert C; von Stackelberg A; Seeger K; Groeneveld TW; Peters C; Klingebiel T; Borkhardt A; Schrappe M; Escherich G; Henze G
    Eur J Cancer; 2013 Apr; 49(6):1346-55. PubMed ID: 23265714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Importance of effective central nervous system therapy in isolated bone marrow relapse of childhood acute lymphoblastic leukemia. BFM (Berlin-Frankfurt-Münster) Relapse Study Group.
    Bührer C; Hartmann R; Fengler R; Schober S; Arlt I; Loewke M; Henze G
    Blood; 1994 Jun; 83(12):3468-72. PubMed ID: 8204875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group.
    Bader P; Kreyenberg H; Henze GH; Eckert C; Reising M; Willasch A; Barth A; Borkhardt A; Peters C; Handgretinger R; Sykora KW; Holter W; Kabisch H; Klingebiel T; von Stackelberg A;
    J Clin Oncol; 2009 Jan; 27(3):377-84. PubMed ID: 19064980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring of minimal residual disease after allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia allows for the identification of impending relapse: results of the ALL-BFM-SCT 2003 trial.
    Bader P; Kreyenberg H; von Stackelberg A; Eckert C; Salzmann-Manrique E; Meisel R; Poetschger U; Stachel D; Schrappe M; Alten J; Schrauder A; Schulz A; Lang P; Müller I; Albert MH; Willasch AM; Klingebiel TE; Peters C
    J Clin Oncol; 2015 Apr; 33(11):1275-84. PubMed ID: 25605857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission after intensive primary and relapse therapy according to the BFM- and CoALL-protocols: results of the German Cooperative Study.
    Dopfer R; Henze G; Bender-Götze C; Ebell W; Ehninger G; Friedrich W; Gadner H; Klingebiel T; Peters C; Riehm H
    Blood; 1991 Nov; 78(10):2780-4. PubMed ID: 1824271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage--a report of the Berlin-Frankfurt-Münster Group.
    Reiter A; Schrappe M; Parwaresch R; Henze G; Müller-Weihrich S; Sauter S; Sykora KW; Ludwig WD; Gadner H; Riehm H
    J Clin Oncol; 1995 Feb; 13(2):359-72. PubMed ID: 7844597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica.
    Conter V; Aricò M; Valsecchi MG; Rizzari C; Testi AM; Messina C; Mori PG; Miniero R; Colella R; Basso G
    J Clin Oncol; 1995 Oct; 13(10):2497-502. PubMed ID: 7595699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.
    Millot F; Suciu S; Philippe N; Benoit Y; Mazingue F; Uyttebroeck A; Lutz P; Mechinaud F; Robert A; Boutard P; Marguerite G; Ferster A; Plouvier E; Rialland X; Behard C; Plantaz D; Dresse MF; Philippet P; Norton L; Thyss A; Dastugue N; Waterkeyn C; Vilmer E; Otten J;
    J Clin Oncol; 2001 Apr; 19(7):1935-42. PubMed ID: 11283125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unrelated donor stem cell transplantation compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission: a matched-pair analysis.
    Borgmann A; von Stackelberg A; Hartmann R; Ebell W; Klingebiel T; Peters C; Henze G;
    Blood; 2003 May; 101(10):3835-9. PubMed ID: 12732501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98.
    von Neuhoff C; Reinhardt D; Sander A; Zimmermann M; Bradtke J; Betts DR; Zemanova Z; Stary J; Bourquin JP; Haas OA; Dworzak MN; Creutzig U
    J Clin Oncol; 2010 Jun; 28(16):2682-9. PubMed ID: 20439630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Other (Non-CNS/Testicular) Extramedullary Localizations of Childhood Relapsed Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma-A Report from the ALL-REZ Study Group.
    Lissat A; van Schewick C; Steffen IG; Arakawa A; Bourquin JP; Burkhardt B; Henze G; Mann G; Peters C; Sramkova L; Eckert C; von Stackelberg A; Chen-Santel C
    J Clin Med; 2021 Nov; 10(22):. PubMed ID: 34830574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group.
    Eckert C; Henze G; Seeger K; Hagedorn N; Mann G; Panzer-Grümayer R; Peters C; Klingebiel T; Borkhardt A; Schrappe M; Schrauder A; Escherich G; Sramkova L; Niggli F; Hitzler J; von Stackelberg A
    J Clin Oncol; 2013 Jul; 31(21):2736-42. PubMed ID: 23775972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Outcome of childhood high-risk acute lymphoblastic leukemia treated with the ALL-BFM 95 protocol].
    Ruan YS; Wu XD; Feng XQ; He YL; Zhang YM; Pei FY; Li CF
    Zhongguo Dang Dai Er Ke Za Zhi; 2015 Apr; 17(4):327-31. PubMed ID: 25919549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ALL-REZ BFM--the consecutive trials for children with relapsed acute lymphoblastic leukemia.
    Henze G; v Stackelberg A; Eckert C
    Klin Padiatr; 2013 May; 225 Suppl 1():S73-8. PubMed ID: 23700062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of CNS recurrence in childhood ALL: results with reduced radiotherapy combined with CNS-directed chemotherapy in four consecutive ALL-BFM trials.
    Schrappe M; Reiter A; Henze G; Niemeyer C; Bode U; Kühl J; Gadner H; Havers W; Plüss H; Kornhuber B; Zintl F; Ritter J; Urban C; Niethammer D; Riehm H
    Klin Padiatr; 1998; 210(4):192-9. PubMed ID: 9743952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85). A relapse study of the BFM group.
    Henze G; Fengler R; Hartmann R; Kornhuber B; Janka-Schaub G; Niethammer D; Riehm H
    Blood; 1991 Sep; 78(5):1166-72. PubMed ID: 1878583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the berlin-frankfurt-muenster group.
    Burkhardt B; Reiter A; Landmann E; Lang P; Lassay L; Dickerhoff R; Lakomek M; Henze G; von Stackelberg A
    J Clin Oncol; 2009 Jul; 27(20):3363-9. PubMed ID: 19433688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stem-cell transplantation in children with acute lymphoblastic leukemia: A prospective international multicenter trial comparing sibling donors with matched unrelated donors-The ALL-SCT-BFM-2003 trial.
    Peters C; Schrappe M; von Stackelberg A; Schrauder A; Bader P; Ebell W; Lang P; Sykora KW; Schrum J; Kremens B; Ehlert K; Albert MH; Meisel R; Matthes-Martin S; Gungor T; Holter W; Strahm B; Gruhn B; Schulz A; Woessmann W; Poetschger U; Zimmermann M; Klingebiel T
    J Clin Oncol; 2015 Apr; 33(11):1265-74. PubMed ID: 25753432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.